Header Logo

Connection

NICOLA HANANIA to Quality of Life

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Quality of Life.
NICOLA HANANIA
Connection Strength
4.436
Quality of Life
  1. Sex differences and determinants of anxiety symptoms in patients with COPD initiating pulmonary rehabilitation. Respir Med. 2024 06; 227:107633.
    View in: PubMed
    Score: 0.470
  2. The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety. Respir Med. 2022 06; 197:106850.
    View in: PubMed
    Score: 0.409
  3. Predictors of premature discontinuation and prevalence of dropouts from a pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease. Respir Med. 2022 03; 193:106742.
    View in: PubMed
    Score: 0.403
  4. Long-Term Benefits of Pulmonary Rehabilitation in Patients With COPD: A 2-Year Follow-Up Study. Chest. 2021 03; 159(3):967-974.
    View in: PubMed
    Score: 0.369
  5. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018; 13:499-508.
    View in: PubMed
    Score: 0.306
  6. COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. J Fam Pract. 2018 02; 67(2 Suppl):S11-S18.
    View in: PubMed
    Score: 0.306
  7. Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. J Am Med Dir Assoc. 2017 Dec 01; 18(12):1063-1068.
    View in: PubMed
    Score: 0.302
  8. Factors associated with depressive symptoms in uncontrolled asthmatics. J Asthma. 2018 05; 55(5):555-560.
    View in: PubMed
    Score: 0.297
  9. The Responsiveness of the Anxiety Inventory for Respiratory Disease Scale Following Pulmonary Rehabilitation. Chest. 2016 07; 150(1):188-95.
    View in: PubMed
    Score: 0.268
  10. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Ann Allergy Asthma Immunol. 2023 02; 130(2):206-214.e2.
    View in: PubMed
    Score: 0.106
  11. Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. Int J Chron Obstruct Pulmon Dis. 2021; 16:865-875.
    View in: PubMed
    Score: 0.095
  12. The many faces of asthma-chronic obstructive pulmonary disease overlap. Curr Opin Pulm Med. 2019 01; 25(1):1-10.
    View in: PubMed
    Score: 0.081
  13. Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. Chest. 2017 Jan; 151(1):68-77.
    View in: PubMed
    Score: 0.069
  14. Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016 07; 13(7):1016-25.
    View in: PubMed
    Score: 0.068
  15. Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts. Chest. 2016 Apr; 149(4):927-35.
    View in: PubMed
    Score: 0.066
  16. Hospital management of acute exacerbations of chronic obstructive pulmonary disease. J Hosp Med. 2015 May; 10(5):328-39.
    View in: PubMed
    Score: 0.063
  17. Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013; 8:117-25.
    View in: PubMed
    Score: 0.055
  18. Asthma outcomes revisited. Curr Opin Pulm Med. 2013 Jan; 19(1):6-12.
    View in: PubMed
    Score: 0.054
  19. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. Health Qual Life Outcomes. 2012 Aug 23; 10:100.
    View in: PubMed
    Score: 0.052
  20. Racial differences in quality of life in patients with COPD. Chest. 2011 Nov; 140(5):1169-1176.
    View in: PubMed
    Score: 0.048
  21. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 05 03; 154(9):573-82.
    View in: PubMed
    Score: 0.048
  22. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011 Jan 11; 12:6.
    View in: PubMed
    Score: 0.047
  23. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18; 69(9):1205-16.
    View in: PubMed
    Score: 0.042
  24. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 Jun 27; 390(24):2274-2283.
    View in: PubMed
    Score: 0.030
  25. Identification of sleep phenotypes in COPD using machine learning-based cluster analysis. Respir Med. 2024 06; 227:107641.
    View in: PubMed
    Score: 0.030
  26. An Update on Patient-Reported Outcomes in Asthma. Chest. 2024 May; 165(5):1049-1057.
    View in: PubMed
    Score: 0.029
  27. Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma. Respir Med. 2024 03; 223:107537.
    View in: PubMed
    Score: 0.029
  28. Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023 08; 62(2).
    View in: PubMed
    Score: 0.028
  29. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023 Jul 20; 389(3):205-214.
    View in: PubMed
    Score: 0.028
  30. Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic Asthma. J Allergy Clin Immunol Pract. 2023 03; 11(3):873-884.e11.
    View in: PubMed
    Score: 0.027
  31. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020 11; 125(5):565-576.e1.
    View in: PubMed
    Score: 0.022
  32. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1043-1057.
    View in: PubMed
    Score: 0.022
  33. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1058-1068.
    View in: PubMed
    Score: 0.022
  34. Design of a home-based intervention for Houston-area African-American adults with asthma: Methods and lessons learned from a pragmatic randomized trial. Contemp Clin Trials. 2020 04; 91:105977.
    View in: PubMed
    Score: 0.022
  35. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1023-1042.
    View in: PubMed
    Score: 0.022
  36. Characteristics and outcomes of older adults with long-standing versus late-onset asthma. J Asthma. 2017 04; 54(3):223-229.
    View in: PubMed
    Score: 0.017
  37. Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016 06; 115:7-12.
    View in: PubMed
    Score: 0.017
  38. A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges. Int J Chron Obstruct Pulmon Dis. 2015; 10:725-38.
    View in: PubMed
    Score: 0.016
  39. A simplified score to quantify comorbidity in COPD. PLoS One. 2014; 9(12):e114438.
    View in: PubMed
    Score: 0.015
  40. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013 Aug; 10(4):482-92.
    View in: PubMed
    Score: 0.014
  41. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Adv Ther. 2009 Nov; 26(11):1024-34.
    View in: PubMed
    Score: 0.011
  42. It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.